Cargando…

The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.

The pharmacokinetics of 5-fluorouracil (5FU) following its administration via the hepatic artery in conjunction with biodegradable albumin microspheres and angiotensin II have been studied. Peripheral venous concentrations of 5FU are lower and plasma clearance values higher following intrahepatic ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, J. A., Kerr, D. J., Watson, D. G., Willmott, N., Bates, C. D., McKillop, J. H., McArdle, C. S.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971687/
https://www.ncbi.nlm.nih.gov/pubmed/2372496
_version_ 1782134963846512640
author Goldberg, J. A.
Kerr, D. J.
Watson, D. G.
Willmott, N.
Bates, C. D.
McKillop, J. H.
McArdle, C. S.
author_facet Goldberg, J. A.
Kerr, D. J.
Watson, D. G.
Willmott, N.
Bates, C. D.
McKillop, J. H.
McArdle, C. S.
author_sort Goldberg, J. A.
collection PubMed
description The pharmacokinetics of 5-fluorouracil (5FU) following its administration via the hepatic artery in conjunction with biodegradable albumin microspheres and angiotensin II have been studied. Peripheral venous concentrations of 5FU are lower and plasma clearance values higher following intrahepatic arterial administration compared with a similar dose administered by intravenous infusion over both 2 h and 24 h. For the 2 h drug infusions, plasma 5FU concentrations following co-treatment with angiotensin II and microspheres via the hepatic artery were intermediate between those of arterial and venous infusions of 5FU alone. There was a trend towards the peak plasma drug concentrations and the area under the plasma concentration-time curve (AUC) being significantly lower following co-treatment with angiotensin II and microspheres compared with intra-arterial and intravenous infusions of 5FU over 24 h. Co-administration of 5FU, angiotensin II and microspheres via the hepatic artery may reduce drug exposure in the systemic compartment and therefore may increase the therapeutic ratio of 5FU administration via the hepatic artery.
format Text
id pubmed-1971687
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19716872009-09-10 The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases. Goldberg, J. A. Kerr, D. J. Watson, D. G. Willmott, N. Bates, C. D. McKillop, J. H. McArdle, C. S. Br J Cancer Research Article The pharmacokinetics of 5-fluorouracil (5FU) following its administration via the hepatic artery in conjunction with biodegradable albumin microspheres and angiotensin II have been studied. Peripheral venous concentrations of 5FU are lower and plasma clearance values higher following intrahepatic arterial administration compared with a similar dose administered by intravenous infusion over both 2 h and 24 h. For the 2 h drug infusions, plasma 5FU concentrations following co-treatment with angiotensin II and microspheres via the hepatic artery were intermediate between those of arterial and venous infusions of 5FU alone. There was a trend towards the peak plasma drug concentrations and the area under the plasma concentration-time curve (AUC) being significantly lower following co-treatment with angiotensin II and microspheres compared with intra-arterial and intravenous infusions of 5FU over 24 h. Co-administration of 5FU, angiotensin II and microspheres via the hepatic artery may reduce drug exposure in the systemic compartment and therefore may increase the therapeutic ratio of 5FU administration via the hepatic artery. Nature Publishing Group 1990-06 /pmc/articles/PMC1971687/ /pubmed/2372496 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Goldberg, J. A.
Kerr, D. J.
Watson, D. G.
Willmott, N.
Bates, C. D.
McKillop, J. H.
McArdle, C. S.
The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
title The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
title_full The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
title_fullStr The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
title_full_unstemmed The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
title_short The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
title_sort pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971687/
https://www.ncbi.nlm.nih.gov/pubmed/2372496
work_keys_str_mv AT goldbergja thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases
AT kerrdj thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases
AT watsondg thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases
AT willmottn thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases
AT batescd thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases
AT mckillopjh thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases
AT mcardlecs thepharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases
AT goldbergja pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases
AT kerrdj pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases
AT watsondg pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases
AT willmottn pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases
AT batescd pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases
AT mckillopjh pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases
AT mcardlecs pharmacokineticsof5fluorouraciladministeredbyarterialinfusioninadvancedcolorectalhepaticmetastases